论文部分内容阅读
普伐他丁(pravastatin)是一种亲水性HMG-COA还原酶抑制剂,能抑制胆固醇的合成,国外已用于治疗高脂血症。我院于1995年7月至1996年4月采用中美上海施贵宝制药公司生产的普伐他丁(商品名普拉固)治疗高胆固醇血症,效果满意,现报道如下。 对象和方法 1.对象:本院心内科住院或门诊病人60例,年龄30～70岁,均保持平常饮食,至少4周内未用任何调脂药,间隔1周各测血脂1次,两次血清胆固醇(TC)水平均≥5.98mmol/L(230mg/dl),且排除下列情况:近6个月内患脑血管意外、心肌梗塞、经历大手术或严重创伤;药物引起的继发性高脂血症、甲状腺疾患、糖尿病、肝肾疾病;恶性肿瘤等疾病。其中伴甘油三酯(TG)≥
Pravastatin, a hydrophilic HMG-COA reductase inhibitor, inhibits cholesterol synthesis and has been used abroad for the treatment of hyperlipidemia. Our hospital in July 1995 to April 1996 using Sino-US Shanghai Squibb pharmaceutical company produced pravastatin (Pulai solid) treatment of hypercholesterolemia, with satisfactory results are reported below. Subjects and Methods 1. Subjects: 60 hospitalized or outpatient patients in our Department of Cardiology, aged 30 to 70 years old, maintained their normal diet and had not taken any lipid-adjusting drugs for at least 4 weeks, Serum cholesterol (TC) levels were ≥ 5.98 mmol / L (230 mg / dl), and excluded the following: within the past 6 months of cerebrovascular accident, myocardial infarction, underwent major surgery or severe trauma; drug-induced secondary Hyperlipidemia, thyroid disease, diabetes, liver and kidney disease; cancer and other diseases. Including triglycerides (TG) ≥